Superiority of a novel Mp1p antigen detection enzyme immunoassay compared to standard BACTEC blood culture in the diagnosis of talaromycosis

Nguyen T.M. Thu\textsuperscript{1,7*}, Jasper F.W. Chan\textsuperscript{2,5*}, Vo Trieu Ly\textsuperscript{3,4}, Hoa T Ngo\textsuperscript{1}, Ha T.A. Hien\textsuperscript{1}, Nguyen P.H. Lan\textsuperscript{3}, Nguyen V.V. Chau\textsuperscript{3}, Jian-Piao Cai\textsuperscript{2}, Patrick C.Y. Woo\textsuperscript{2}, Jeremy N Day\textsuperscript{1,6}, Rogier van Doorn\textsuperscript{1,6}, Guy Thwaites\textsuperscript{1,6}, John Perfect\textsuperscript{7}, KY Yuen\textsuperscript{2,5*} and Thuy Le\textsuperscript{1,7*}

*\textsuperscript{*} These first and senior authors contributed equally to this article

Affiliations: \textsuperscript{1}Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam; \textsuperscript{2}State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong; \textsuperscript{3}Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam; \textsuperscript{4}University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam; \textsuperscript{5}Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University, Haikou, Hainan, China; \textsuperscript{6}Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, UK; \textsuperscript{7}Division of Infectious Diseases and International Health, Duke University School of Medicine, Durham, NC, USA

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author:
Thuy Le, MD, PhD
Division of Infectious Diseases and International Health, Duke University School of Medicine,
Email: thuy.le@duke.edu; Phone: 919.668.5053; Fax: 919.681.8902

Summary: The novel Mp1p enzyme immunoassay is superior in sensitivity compared to standard BACTEC blood culture and substantially shortens time-to-diagnosis of talaromycosis. This is a novel non-culture-based tool for rapid diagnosis, enabling early treatment and potentially reducing mortality.
Abstract

BACKGROUND: Talaromycosis is an invasive mycosis endemic in Southeast Asia and causes substantial morbidity and mortality in individuals with advanced HIV disease. Current diagnosis relies on isolating *Talaromyces marneffei* in cultures, which takes up to 14 days and is detectable only during late-stage infection, leading to high mortality.

METHODS: In this retrospective case-control study, we assessed the accuracy of a novel Mp1p antigen-detecting enzyme immunoassay (EIA) in stored plasma samples of 372 patients who had culture-proven talaromycosis from blood or sterile body fluids (reference standard) and of 517 individuals without talaromycosis (338 healthy volunteers; 179 with other infections). All participants were recruited between 2011-2017 in Vietnam.

RESULTS: 66.1% and 75.4% of cases and controls were male; the median age was 33 and 37, respectively. All cases were HIV-infected; median CD4 count was 10 cells/mm$^3$. At an optical density cut-off of 0.5, the specificity was 98.1% (95% CI: 96.3%-99.0%); the sensitivity was superior to blood culture, 86.3% (95% CI: 82.3%-89.5%) versus 72.8% (95% CI: 68.0%-77.2%), $P<0.001$, McNemar test. The time-to-diagnosis was 6 hours versus 6.6 ± 3.0 days for blood culture. Paired plasma and urine testing in the same patients (N=269) significantly increased sensitivity compared to testing plasma alone $P<0.001$, or testing urine alone $P=0.02$, McNemar tests.

CONCLUSIONS: The Mp1p EIA is highly specific and is superior in sensitivity and time-to-diagnosis compared to blood culture for the diagnosis of talaromycosis. Paired plasma and urine
testing further increases sensitivity, introducing a new tool for rapid diagnosis, enabling early treatment and potentially reducing mortality.

Key words: Talaromycosis, penicilliosis, Talaromyces marneffei, Penicillium marneffei, Mp1p enzyme immunoassay
Introduction

Talaromycosis (formerly penicilliosis) is an invasive mycosis caused by the dimorphic fungus *Talaromyces marneffei* (Tm) endemic in Southeast Asia and southern China\(^1\). Talaromycosis ranks third as the most common HIV-associated opportunistic infections, accounting for up to 16% of HIV admissions, and is a leading cause of HIV-associated death in highly-endemic countries of Thailand, Vietnam, and China\(^2^\text{-}^5\). Incidence is rising in non-HIV-infected individuals who have a primary or secondary immunodeficiency condition\(^6\), and is rising in immigrants and returning travelers from Southeast Asia\(^7\)\(^,\)\(^8\). Patients with advanced HIV disease (CD4 count <100 cells/mm\(^3\)) develop an indolent infection over months before progressing to a multi-organ disseminated infection involving the lung, skin, oropharyngeal mucosa, gastrointestinal track, lymphatic system, liver, spleen, blood stream, and bone marrow\(^1\)\(^,\)\(^2\). The mortality despite antifungal therapy is up to 50% at three months in both HIV- and non-HIV-infected individuals\(^2\)\(^,\)\(^5\)\(^,\)\(^9\)\(^,\)\(^10\).

A critical barrier to reducing talaromycosis mortality is our inability to make an early diagnosis. The current diagnosis relies on culture isolation of Tm from blood and clinical specimens, which takes up to 14 days\(^2\). In a recent talaromycosis treatment trial in Vietnam, 38/573 (6.6%) of patients died before culture became positive\(^9\). Blood culture is positive only when infection progresses to its advanced stage and misses 30% of infections in HIV-infected and 50% of non-HIV-infected patients\(^2\)\(^,\)\(^10\). In a cohort of 668 patients in Guangzhou, China, the mortality increased from 24.3% to 50.6% due to late diagnosis, and was 100% when the diagnosis was missed\(^3\).
Antigen detection is accurate, rapid, inexpensive, does not require sophisticated equipment, and has become a standard diagnostic for other fungal infections including cryptococcosis, aspergillosis, and histoplasmosis\textsuperscript{11-13}. Efforts to develop enzyme immunoassays (EIAs) for talaromycosis have been hampered by the use of polyclonal antibodies (PAbs) which lack sensitivity and specificity\textsuperscript{14-19}. Recently a promising monoclonal-antibody (MAb)-based (MAb 4D1) inhibitory EIA and its immunochromatographic platform were developed in Thailand, but diagnostic accuracy has only been evaluated in small selected clinical samples\textsuperscript{20,21}. We have previously discovered a Tm-unique \textit{MPI} gene which encodes a galactomannoprotein Mp1p located throughout the cell wall of Tm yeast\textsuperscript{22}. The Mp1p antigen is abundantly secreted and is an important virulence factor for Tm\textsuperscript{23}, making it an ideal and specific target for immunodiagnostics. We have cloned Mp1p and developed an Mp1p EIA using mouse MAbs and rabbit PAbs generated against the recombinant Mp1p\textsuperscript{24,25}. No cross-reactivity occurred with 11 common pathogenic fungi including \textit{Cryptococcus}, \textit{Candida}, \textit{Aspergillus}, and \textit{Histoplasma} spp. The Mp1p EIA was positive in 15/20 (75.0\%) of culture-confirmed talaromycosis patients and negative in 537/540 (99.4\%) of control participants (15 with invasive mycoses, 525 healthy volunteers), demonstrating excellent analytical and clinical specificities\textsuperscript{25}. Here, we report the results of a diagnostic accuracy study of the Mp1p EIA compared with blood culture for the diagnosis of talaromycosis in large patient cohorts in Vietnam.

\section*{Methods}

\subsection*{Ethics Statement}

The study was approved by the ethics and scientific committee of the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City (HCMC) as a sub-study of the Itraconazole Versus
Amphotericin B for Penicilliosis (IVAP) randomized controlled trial (approval number: 329/QD-BVBND). Control plasma samples were from a contemporaneous study of risk factors for *Streptococcus suis* infections (approval number: 326/QD-BVBND). All participants gave informed consent for their specimens to be stored and used in this research.

**Study design and populations**

In this retrospective diagnostic case-control study, cases included all culture-proven talaromycosis patients who participated in the IVAP trial at five hospitals across Vietnam between 2012 and 2016. The IVAP trial recruited 440/573 (77.0%) talaromycosis patients who were screened for eligibility, representing a wide spectrum of disease severity. The reference standard was culture-proven talaromycosis, defined as a compatible clinical syndrome plus positive cultures from blood and/or from skin lesions, lymph nodes, body fluids, bone marrow aspirate. Blood culture was performed for all patients using the standard automated aerobic BACTEC™ bottles. Only plasma and urine specimens that were collected at the same time of the first blood culture collection were used for antigen testing. Control participants included healthy volunteers and patients who were diagnosed with any infectious diseases other than talaromycosis while hospitalized at the HTD between 2011 and 2017. HIV infection was excluded from the control group because a negative blood culture does not rule out talaromycosis in HIV-infected individuals.

**Analytical validation of the Mp1p EIA**

The recombinant Mp1p (rMp1p), mouse MAbs, and rabbit PAbs were obtained from Department of Microbiology, The University of Hong Kong. The Mp1p EIA was validated in our laboratory
at the Oxford University Clinical Research Unit in Vietnam. The analytical limit of detection (LoD) was determined using the 4 Parameter Logistic (4PL) curve fitting on 14 rMp1p concentrations ranging from 1pg/mL to 10,000pg/mL. The LoD was defined as the lowest rMp1p concentration corresponding to an OD value which was reliably distinguished from the mean OD of 3 blank samples. A set of low (200pg/mL), medium (800pg/mL), and high (3,200pg/mL) rMp1p control concentrations was used for experiments to calculate intra-assay and inter-assay variability. The intra-assay variability were determined by running 10 replicates each of rMp1p controls in one experiment. The inter-assay variability were determined by running rMp1p controls in 10 separate experiments. The coefficient of variation (CV) for intra-assay variability should be less than 10%, and the CV for inter-assay variability should be less than 15%.27

Sample preparation and testing

The Mp1p EIA was performed on thawed plasma and urine samples. Briefly, immunoplates (Nunc, Denmark) were coated with the rabbit Mp1p PAbs at concentration of 5µg/mL overnight at 4°C and were further blocked in Tris-base with 0.2% Gelatin and 0.25% Casein at 37°C for 2h. Aliquots of 100µl of undiluted plasma and urine samples were added to the coated wells and incubated at 37°C for 1h. The plate was washed six times with PBS with 0.05% Tween20 (Sigma, MO, USA). After washing, 100µl of 1:1000 diluted mouse Mp1p MAbs conjugated with biotin was added and kept at room temperature (25°C) for 30min, followed by incubation with streptavidin-horseradish peroxidase (Agilent-Dako, CA, USA) for 30min. Tetramethybenzidine (TMB) (Invitrogen, CA, USA) were then added. The reaction was stopped after 10min by the
addition of 0.3M sulfuric acid. The plate was then examined in an ELISA reader (ACTGene, NJ, USA) at 450nm.

Sample size estimates

Power calculations were based on the sensitivity and specificity of the Mp1p EIA we previously published\(^\text{25}\), using the formula for estimating an infinite population proportion\(^\text{28}\). Assuming a sensitivity of 0.75 (error d=0.05), a specificity of 0.99 (error d=0.01), a sample size of 289 cases and 381 controls would provide a power of 80% or higher to demonstrate a sensitivity of at least 70% and a specificity of at least 98% to 100% (\(\alpha=0.05\)) for the Mp1p EIA.

Statistical analyses

The OD distribution between cases and controls were compared using Wilcoxon ranked test. A receiver-operator characteristic (ROC) curve was generated which displayed all sensitivity and specificity pairs for different OD cut-off points using Prism 4.0. The assay cut-off was determined based on the Youden index on the ROC curve which maximizes true-positives and minimizes false-positives. The discrimination power between cases and controls was determined by calculating the area under the ROC curve (AUC) and the 95% confidence intervals (CIs). The point estimates and the 95% CIs for sensitivity and specificity were calculated based on the reference standard. The sensitivities of the Mp1p EIA and of blood culture performed on the same patients were compared using McNemar test. Pairwise comparisons of the sensitivities of the Mp1p EIA performed in plasma, urine, and plasma plus urine from the same patients were performed using McNemar tests. All statistical analyses were performed using R, version 3.6.1.
Results

Characteristics of study participants

Figure 1 shows the selection of the study participants and the specific infectious disease diagnoses of the controls. Of the 440 patients who participated in the IVAP trial, 372 met the inclusion criteria. The median age was 33 (Interquartile Range [IQR]: 29-38) years. 246 (66.1%) were male. All patients were HIV-infected; the median CD4 count was 10 (IQR: 2-22) cells/mm³. Blood culture was positive for Tm in 271 (72.8%, 95% CI: 68.0%-77.2%) patients. The control group included 517 participants: 338 healthy volunteers and 179 patients infected with a spectrum of bacterial, mycobacterial, viral, parasitic, and fungal pathogens. The median age among the controls was 37 (IQR: 27-48) years; 390 (75.4%) were male.

Analytical validation of the Mp1p EIA

Based on the standard curve of rMp1p concentrations and the corresponding OD values, the LoD was at least as low as 62.5 pg/mL, which was the same as the LoD generated in our laboratory in Hong Kong. This demonstrates assay consistency between batches of antibodies and rMp1p and between laboratories. The intra-assay CV (for 10 replicates of 3 controls) was 1.4% (<10%), and the inter-assay CV (for 10 repeated experiments of 3 controls) was 9.2% (<15%), demonstrating good assay reproducibility.

Diagnostic accuracy of the Mp1p EIA in plasma samples

Figure 2A displays the difference in OD distribution of cases and controls which was statistically significant (P<0.001, Wilcoxon rank test). Figure 2B shows the ROC curve plotting true-
positives (sensitivity) against false-positives (1-specificity). The AUC demonstrated a 94.9% accuracy in the discrimination between talaromycosis and non-talaromycosis participants.

At the OD cut-off of 0.5 generated by the Youden index, the diagnostic characteristics of the Mp1p EIA are shown in Table 1. The Mp1p EIA correctly diagnosed talaromycosis in 321/372 (86.3%) patients (95% CI: 82.3%-89.5%); this was superior to blood culture, which correctly diagnosed talaromycosis in 271/372 (72.8%) patients (95% CI: 68.0%-77.2%, P<0.001, McNemar test). The Mp1p EIA correctly excluded talaromycosis in 507/517 (98.1%) patients (95% CI: 96.3%-99.0%). The positive likelihood ratio (+LR) (where LR >1 indicates an association with disease) was 45. The negative likelihood ratio (-LR) (where LR <1 indicates an association with absence of disease) was 0.1.

**Sensitivities of plasma versus urine in paired samples**

Urine samples were collected in the IVAP trial, and paired plasma and urine samples were available for 269/372 (72.3%) talaromycosis cases. More talaromycosis patients were identified in urine than in plasma samples, 232/269 (86.2%, 95% CI: 81.4%-90.0%) versus 223/269 (82.9%, 95% CI: 77.7%-87.1%), but the difference did not reach statistical significance, P=0.06, McNemar test. When testing plasma and urine in combination, 7 additional cases were identified, resulting in a significantly higher sensitivity (239/269, 88.8%, 95% CI: 84.3%-92.2%) compared to testing plasma alone (223/269, 82.9%, 95% CI: 77.7%-87.1%, P<0.001, McNemar test), or to testing urine alone (232/269, 86.2%, 95% CI: 81.4%-90.0%, P=0.02, McNemar test).
Characteristics of 10 controls who tested positive (false-positives) and 51 cases who tested negative (false-negatives)

The 10 false-positives included 6 healthy volunteers and 4 patients who had 3 different infections. Their OD values were in the low positive range (0.54 to 0.96) and were not discriminatory between healthy volunteers and hospitalized controls. There was no clustering of infections to suggest cross-reactivity with a specific pathogen.

We compared the characteristics of the 51 false-negatives and the 321 true-positives to identify features associated with a false-negative test. The differences in age, sex, and proportion of patients who initiated antifungal therapy prior to enrollment were not statistically significant between the groups. The false-negatives had fewer cases with positive blood-culture (58.8% vs. 74.1%, \( P=0.036 \)), and the time-to-positive-culture was longer (9.0 vs. 6.6 days, \( P=0.003 \)), indicating that lower blood fungal burden is associated with a false-negative test. Urine test was positive in 16/46 (34.8%) false-negative samples, suggesting that urine is more sensitive than plasma for TmAg testing. Urine samples were not available in control participants; therefore, assessment of specificity in urine could not be performed.

Incidentally, we discovered that one of the five study sites performs fungal blood cultures when a disseminated fungal infection is suspected. This is done using chloramphenicol-treated Sabouraud agar, and the cultures are kept for 10 instead of 5 days for the standard BACTEC blood culture system. Compared to the other four sites, this site has significantly higher proportion of patients with positive blood cultures (114/130, 87.7% versus 154/242, 63.6%, \( P<0.001 \), Chi-square test), longer time-to-positive-culture (7.6 ± 2.7 days versus 6.2 ± 2.8 days,
P<0.001, t-test), and therefore a lower sensitivity of the Mp1p EIA (104/130, 80.0%, 95% CI: 72.3% - 86.0% versus 217/243, 89.7%, 95% CI: 85.2% - 92.9%, P=0.01, Chi-square test).

Discussion

Relying on culture-based methods to diagnose talaromycosis is suboptimal. Blood cultures become positive only during late-stage infections, and the slow growth of the organism, taking up to 14 days to grow, contributes to the missed or late diagnosis of 30%-50% of infections\textsuperscript{2,10}. This has clear implications for the implementation of timely treatment, and indeed currently the diagnosis is made after death in 7% of patients\textsuperscript{9}. While a presumptive diagnosis can be made rapidly based on microscopy of skin lesions, skin lesions are a late manifestation of disseminated disease and are absent in up to 60% of patients\textsuperscript{10}. Delay in diagnosis is associated with high mortality\textsuperscript{2,3}. In our robustly-powered study from Vietnam, we found the Mp1p EIA to have excellent clinical specificity (98.1% in 517 controls), consistent with our previous results from Hong Kong (99.4% in 540 controls)\textsuperscript{25}. The sensitivity was superior to standard BACTEC blood culture (86.3% versus 72.8%), and higher than our previous estimate (75.0% in 20 cases), likely reflecting a more precise measure due to the increased sample size\textsuperscript{25}. We also found the Mp1p EIA to be sensitive when testing urine, comparing favorably with plasma and offering significantly increased sensitivity when the result was paired with that of plasma testing, increasing from 82.9% to 88.8%. Furthermore, the time-to-result was substantially faster, permitting a diagnosis on average 6 days faster than would be confirmed by culture. Therefore, we believe our assay has the potential to significantly improve the management of patients with talaromycosis.
The Mp1p EIA offers several advantages over other MAb-based immunoassays in development. Comparing to the MAb-based 4D1 inhibitory EIA\textsuperscript{20}, the Mp1p EIA detects a Tm-specific mannoprotein\textsuperscript{22,25} rather than non-specific cytoplasmic antigens. It directly measures antigen binding instead of competitive interference, and is simpler to perform. The sensitivity was reported to be 100\% for the MAb-4D1 EIA\textsuperscript{20} and was 87.9\% for its point-of-care immunochromatographic platform\textsuperscript{21}. However, similar to other antigen-detection studies for talaromycosis to date\textsuperscript{14-18,29}, the sample sizes were small (N=45, N=66, respectively). Reference samples were not systematically selected; all cases were blood-culture positive, which is not representative of the disease spectrum in clinical practice, and thus is bias towards higher sensitivity. The prevalence of blood-culture-positivity in our study was 72.8\% which is consistent with published real-world patient cohorts\textsuperscript{23,30,31}.

An alternative approach for diagnosis to culture and antigen testing is nucleic acid amplification tests, such as real-time PCR. We found our assay to have higher sensitivity than real-time PCR assays in development (sensitivity range 70-80\%)\textsuperscript{32-36}. This is likely because the assay directly detects an antigen abundantly present in patients’ samples, whereas PCR assays require DNA extraction with substantial DNA loss. Moreover, the EIA is easier to perform, cheaper, does not require sophisticated equipment or technician skills, and has the potential to be developed as a point of care test. We found the Mp1p EIA produces consistent standard curves between laboratories and batches of antibodies, and was highly reproducible. These characteristics make it a good candidate for development for clinical use. A commercial version of the Mp1p EIA was approved in China in October 2018. Efforts to systematically validate the commercial Mp1p EIA and efforts to develop Mp1p point-of-care platforms are underway and are promising.
We made an incidental finding during the evaluation of false-negatives that has important implications for change of practice. We discovered that the use of a simple fungal blood culture method using an antibiotic-containing media and extending culture time from five to ten days, as practice at one of our study sites, resulted in a higher proportion of blood-culture-positivity (87.7% vs. 63.6%). At this site, fungal blood cultures were performed at physician request only; the extension of this to all patients suspected of having invasive fungal infections might result in significantly increased microbiological confirmation.

Our study has limitations. First, we excluded HIV-infected patients from the control group because we could not exclude talaromycosis in HIV patients on the basis of negative-blood-culture alone. Our specificity estimate is therefore not based on a population at high risk for talaromycosis. Second, our samples were collected between 2011-2017; protein in older samples may have significantly degraded, which is likely to lead to an underestimation of assay sensitivity. Finally, although this is the most robust diagnostic study for talaromycosis to date, the retrospective case-control design only give estimates of diagnostic accuracy when the diagnosis is already known. Prospective diagnostic studies are required and are currently underway to determine the diagnostic utilities of the Mp1p EIA in patient populations who are at risk for talaromycosis (ClinicalTrials.gov: NCT04033120).

**Conclusions**

The Mp1p EIA is highly specific and is superior to standard BACTEC blood culture in sensitivity and in time-to-result for diagnosing talaromycosis. Urine is as good as plasma as a
substrate for antigen testing, and paired plasma and urine testing further improves sensitivity. Fungal blood culture may be superior to standard blood culture and should be performed for patients with advanced HIV suspected of having disseminated fungal infections.
Contributions

Study concept and design: Yuen and Le. Obtaining Funding: Le. Clinical and microbiology data acquisition: Thu, Ly, Ngo, Hien, Lan, Chau, Le. Laboratory work: Thu, Chan, Cai. Data analyses: Thu, Chan, Le. Interpretation of data: Thu, Chan, Woo, Day, van Doorn, Thwaites, Perfect, Yuen, Le. Drafting the manuscript: Thu, Chan, Yuen, Le. Critical revision of the manuscript for intellectual content: Chau, Woo, Day, van Doorn, Thwaites, Perfect. All authors contributed to and approved the final manuscript.

Acknowledgements

We thank all patients who participated in this study. We thank all investigators and study staff from 5 hospitals across Vietnam and all supporting staff from the Clinical Trials Units at the Oxford University Clinical Research Unit in Vietnam who worked together over 5 years to deliver the IVAP trial.

Funding

This study was funded by the Medical Research Council, the Department for International Development; the Wellcome Trust in the United Kingdom through the Joint Global Health Trials Grant (grant number G1100682 to Le); the National Institute of Health (grant numbers NIH R01AI143409 to Le and NIH P30AI064518, with a Duke Center for AIDS Research’s Faculty Development subaward to Le); and donations of Marina Man-Wai Lee and the Hong Kong Hainan Commercial Association South China Microbiology Research Fund.
Conflicts of interest

Patrick C. Y. Woo has provided scientific advisory/laboratory services for Gilead Sciences, International Health Management Associates, Merck & Corporation, and Pfizer.

John Perfect reports research grants from Merck, Astellas, F2G, Scynexis, Pfizer, Amplyx, Ampili, Minnetronix, and Matinas; and non-financial support from Merck, Astellas, F2G, and Scynexis, outside the submitted work. KY Yuen is issued US Patent 5,973,131. Thuy Le has received investigator-initiated research funding from Gilead Sciences outside of the submitted work. The remaining authors declare that they have no conflicts of interest.
References

1. Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. *The Lancet Infectious diseases* 2017; **17**(11): e334-e43.
2. Le T, Wolbers M, Chi NH, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated *Penicillium marneffei* infection in Ho Chi Minh City, Viet Nam. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 2011; **52**(7): 945-52.
3. Hu Y, Zhang J, Li X, et al. *Penicillium marneffei* infection: an emerging disease in mainland China. *Mycopathologia* 2013; **175**(1-2): 57-67.
4. Sirisanthana T, Supparatpinyo K. Epidemiology and management of penicilliosis in human immunodeficiency virus-infected patients. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases* 1998; **3**(1): 48-53.
5. Jiang J, Meng S, Huang S, et al. Effects of *Talaromyces marneffei* infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2018.
6. Chan JF, Lau SK, Yuen KY, Woo PC. *Talaromyces (Penicillium) marneffei* infection in non-HIV-infected patients. *Emerging microbes & infections* 2016; **5**: e19.
7. Cristofaro P, Mileno MD. *Penicillium marneffei* infection in HIV-infected travelers. *AIDS alert* 2006; **21**(12): 140-2.
8. Antinori S, Gianelli E, Bonaccorso C, et al. Disseminated *Penicillium marneffei* infection in an HIV-positive Italian patient and a review of cases reported outside endemic regions. *Journal of travel medicine* 2006; **13**(3): 181-8.
9. Le T, Kinh NV, Cuc NTK, et al. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. *The New England journal of medicine* 2017; **376**(24): 2329-40.
10. Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. *BMC infectious diseases* 2013; **13**: 464.
11. Rajasingham R, Wake RM, Beyene T, Katende A, Letang E, Boulware DR. Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. *Journal of clinical microbiology* 2019; **57**(1).
12. Nacher M, Blanchet D, Bongomin F, et al. Histoplasma capsulatum antigen detection tests as an essential diagnostic tool for patients with advanced HIV disease in low and middle income countries: A systematic review of diagnostic accuracy studies. *PLoS neglected tropical diseases* 2018; **12**(10): e0006802.
13. Marr KA, Datta K, Mehta S, et al. Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 2018; **67**(11): 1705-11.
14. Chaityaroj SC, Chawengkittikul R, Sirisinha S, Watkins P, Sinouplprasert Y. Antigen detection assay for identification of *Penicillium marneffei* infection. *Journal of clinical microbiology* 2003; **41**(1): 432-4.
15. Desakorn V, Simpson AJ, Wuthiekanun V, et al. Development and evaluation of rapid urinary antigen detection tests for diagnosis of penicilliosis *marneffei*. *Journal of clinical microbiology* 2002; **40**(9): 3179-83.
16. Kaufman L, Standard PG, Jalbert M, Kantipong P, Limpakarnjanarat K, Mastro TD. Diagnostic antigenemia tests for penicilliosis marneffei. *Journal of clinical microbiology* 1996; **34**(10): 2503-5.
17. Yuen KY, Wong SS, Tsang DN, Chau PY. Serodiagnosis of *Penicillium marneffei* infection. *Lancet* 1994; **344**(8920): 444-5.

18. Ning C, Lai J, Wei W, et al. Accuracy of rapid diagnosis of *Talaromyces marneffei*: A systematic review and meta-analysis. *PloS one* 2018; **13**(4): e0195569.

19. Desakorn V, Smith MD, Walsh AL, et al. Diagnosis of *Penicillium marneffei* infection by quantitation of urinary antigen by using an enzyme immunoassay. *Journal of clinical microbiology* 1999; **37**(1): 117-21.

20. Prakit K, Nosanchuk JD, Pruksaphon K, Vanittanakom N, Youngchim S. A novel inhibition ELISA for the detection and monitoring of *Penicillium marneffei* antigen in human serum. *European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology* 2016; **35**(4): 647-56.

21. Pruksaphon K, Intaramat A, Ratanabanangkoon K, Nosanchuk JD, Vanittanakom N, Youngchim S. Development and characterization of an immunochromatographic test for the rapid diagnosis of *Talaromyces (Penicillium) marneffei*. *PloS one* 2018; **13**(4): e0195596.

22. Cao L, Chan CM, Lee C, Wong SS, Yuen KY. MP1 encodes an abundant and highly antigenic cell wall mannoprotein in the pathogenic fungus *Penicillium marneffei*. *Infection and immunity* 1998; **66**(3): 966-73.

23. Woo PC, Lau SK, Lau CC, et al. Mp1p Is a Virulence Factor in *Talaromyces (Penicillium) marneffei*. *PLoS neglected tropical diseases* 2016; **10**(8): e0004907.

24. Caol, Chan KM, Chen D, et al. Detection of cell wall mannoprotein Mp1p in culture supernatants of *Penicillium marneffei* and in sera of penicilliosis patients. *Journal of clinical microbiology* 1999; **37**(4): 981-6.

25. Wang YF, Cai JP, Wang YD, et al. Immunoassays based on *Penicillium marneffei* Mp1p derived from *Pichia pastoris* expression system for diagnosis of penicilliosis. *PloS one* 2011; **6**(12): e28796.

26. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. *Clin Biochem Rev* 2008; **29 Suppl 1**: S49-52.

27. Hanneman SK, Cox CD, Green KE, Kang DH. Estimating intra- and inter-assay variability in salivary cortisol. *Biological research for nursing* 2011; **13**(3): 243-50.

28. Chow S-CS, J.; Wang, H.; Lokhnygina, Y Sample Size Calculations in Clinical Research 2nd Edition ed. New York: Marcel Dekker, Inc.; 2008.

29. Pruksaphon K, Intaramat A, Ratanabanangkoon K, Nosanchuk JD, Vanittanakom N, Youngchim S. Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing. *Diagnostic microbiology and infectious disease* 2020; **96**(3): 114959.

30. Larsson M, Nguyen LH, Wertheim HF, et al. Clinical characteristics and outcome of *Penicillium marneffei* infection among HIV-infected patients in northern Vietnam. *AIDS research and therapy* 2012; **9**(1): 24.

31. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated *Penicillium marneffei* infection in southeast Asia. *Lancet* 1994; **344**(8915): 110-3.

32. Hien HT, Thanh TT, Thu NT, et al. Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of *Talaromyces marneffei* MP1 gene in human plasma. *Mycoses* 2016.

33. Li X, Zheng Y, Wu F, et al. Evaluation of quantitative real-time PCR and Platelia galactomannan assays for the diagnosis of disseminated *Talaromyces marneffei* infection. *Medical mycology* 2019.

34. Lu S, Li X, Calderone R, et al. Whole blood Nested PCR and Real-time PCR amplification of *Talaromyces marneffei* specific DNA for diagnosis. *Medical mycology* 2016; **54**(2): 162-8.
35. Pornprasert S, Praparattanapan J, Khamwan C, et al. Development of TaqMan real-time polymerase chain reaction for the detection and identification of *Penicillium marneffei*. *Mycoses* 2009; 52(6): 487-92.
36. Dankai W, Pongpom M, Vanittanakom N. Validation of reference genes for real-time quantitative RT-PCR studies in *Talaromyces marneffei*. *Journal of microbiological methods* 2015; 118: 42-50.
**Figure 1 legend:** The flowchart describes the selection of the study population. Cases included 372 patients from the IVAP (Itraconazole versus Amphotericin for Penicilliosis) trial who had culture-proven talaromycosis and who had plasma samples drawn at the same time of the first blood culture collection. Controls included 517 individuals who were healthy volunteers (N=338) and non-HIV-infected patients hospitalized with a range of common infections (N=179) at the Hospital for Tropical Diseases in Ho Chi Minh city. TP, true positive; FN, false negative; FP, false positive; TN, true negative.

**Figure 2 legend:** (A) the Optical density (OD) distribution of talaromycosis cases and non-talaromycosis controls; the difference in OD distribution was statistically significant; (B) The Receiver Operating Characteristic (ROC) curve demonstrated excellent discrimination (94.9% accuracy) between talaromycosis cases and non-talaromycosis controls. The OD cut-off of 0.5 was the Youden index calculated from the ROC curve which maximizes true-positive, minimizes false-positive, and assumes equal importance of sensitivity and specificity.
Figure 2

(A) OD values at 450nm

(P<0.001) Wilcoxon ranked test
Cut-off = 0.5

Talaromycosis (n=372)
Non Talaromycosis (n=517)

(B) True Positive (Sensitivity)

AUC = 94.9%
(95% CI: 93.2% - 96.6%)

False Positive (100-Specificity)
Table 1: Clinical performance of the Mp1p EIA in 889 study participants, including 372 culture-proven talaromycosis participants and 517 with non-talaromycosis control participants

| OD_{cut-off} = 0.5 | Talaromycosis | Non- talaromycosis | Sum |
|-------------------|---------------|-------------------|-----|
| TmAg positive     | TP            | FP                | 331 |
| OD ≥ 0.5          | 321           | 10                |     |
| TmAg negative     | FN            | TN                | 558 |
| OD < 0.5          | 51            | 507               |     |
| Sum               | 372           | 517               | 889 |

| Diagnostic features | Diagnostic values number (%) | 95% CI        |
|---------------------|-------------------------------|---------------|
| Sensitivity         | 321/372 (86.3%)               | 82.3% - 89.5% |
| Specificity         | 507/517 (98.1%)               | 96.3% - 99.0% |
| Positive likelihood ratio | $\frac{0.863}{(1-0.981)}=45$ |               |
| Negative likelihood ratio | $\frac{(1-0.863)}{0.981}=0.14$ |               |

Note: OD, optical density; TmAg, *Talaromyces marneffei* antigen